1. Home
  2. FORR vs CRDL Comparison

FORR vs CRDL Comparison

Compare FORR & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Forrester Research Inc.

FORR

Forrester Research Inc.

HOLD

Current Price

$5.61

Market Cap

106.6M

ML Signal

HOLD

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.04

Market Cap

97.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FORR
CRDL
Founded
1983
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
106.6M
97.3M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
FORR
CRDL
Price
$5.61
$1.04
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$9.00
AVG Volume (30 Days)
130.1K
376.9K
Earning Date
02-12-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$396,888,000.00
N/A
Revenue This Year
$1.45
N/A
Revenue Next Year
$3.43
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.91
$0.77
52 Week High
$13.33
$1.59

Technical Indicators

Market Signals
Indicator
FORR
CRDL
Relative Strength Index (RSI) 15.63 50.87
Support Level $6.90 $0.95
Resistance Level $7.40 $1.09
Average True Range (ATR) 0.44 0.05
MACD -0.25 0.00
Stochastic Oscillator 7.71 51.76

Price Performance

Historical Comparison
FORR
CRDL

About FORR Forrester Research Inc.

Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Share on Social Networks: